CORRESPONDENCE using OPV during pre-eradication era [2] . The new IAP Immunization timetable has slots for Hepatitis-B and Measles vaccines at 6 and 9 months, respectively. Hence, the new polio schedule will not entail extra visits.
3. It is true that there is no efficacy trial of available rotavirus vaccines in the country and efficacy low in other developing countries. But considering the huge burden of rotavirus disease in India, even a low efficacy should translate in to significant number of lives saved. Higher vaccine efficacy is desirable but should not delay use of an effective public health tool. Regarding proper strain match, it should be noted that there is significant amount of cross-protection offered by the rotavirus vaccines, and even RV1 provided comparable protection against nonvaccine strains in the African trial [3] .
4. There is lack of epidemiological data on the incidence of mumps and rubella in different ages in the country but it is a common knowledge that all these diseases are more common amongst school age group of children. According to most recent unpublished data of the last 18 months (till August 16th 2012) acquired through IAP's IDSurv passive reporting system from pediatricians, school age group has now emerged as the commonest affected group for varicella and mumps in the country. Fifty-five percent of all varicella cases and 65% of all mumps cases are in the age-group of 5-12 years.
The second dose of MMR vaccine is not a "booster"; it is intended to produce immunity in the small number of persons who failed to respond to the first dose. If we delay these 'boosters' to 10 years of age, a significant number of children will be exposed to these diseases, will experience breakthrough diseases (varicella and mumps), and vaccine efficacy especially against varicella will be compromised. Besides, it is more convenient to 'catch' susceptible children before school entry than at later age. 
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